Skip to content
Axcess News – Lifestyle
Author:
VANDA PHARMACEUTICALS INC
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
March 6, 2026
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
March 6, 2026
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
March 5, 2026
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia – A New Chemical Entity Opening New Horizons in Psychiatric Innovation
March 5, 2026
←
Previous Page
1
2